VERU
Veru Inc.
Nasdaq · usd
Veru Inc. (VERU) trades at $2.18 (+2.83%) as of 2:18:18 PM EST on Nov 9, 2026, -11.79% over the past month. Market cap is $36.15M, with 4.9 days to cover in short interest.
Stock performance
How Veru Inc. (VERU) stock has performed from one day to one year, with its 52-week range.
- 1D
- +2.36%
- 1W
- +0.46%
- 1M
- -11.79%
- YTD
- +1.40%
- 1Y
- -16.54%
- 52-wk range
- $2.04 – $7.33
Key statistics
Today's trading snapshot for VERU: day range, open, previous close, volume and market cap.
- Day range
- $2.11 – $2.21
- Open
- $2.12
- Prev close
- $2.12
- Volume
- 97.59K
- Market cap
- $36.15M
- Shares out
- 17.05M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Veru Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 1.27
- P/FCF
- —
- ROE
- -48.0%
- ROA
- -36.8%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 6, 2026
8-K filings
Material corporate events Veru Inc. has disclosed to the SEC on Form 8-K.
- Strategic initiativeSep 8, 2026
The Company has made the strategic decision to expand its current drug development pipeline to advance sabizabulin as a potential novel treatment for patients whose metastatic pancreatic cancer has become resistant to daraxonrasib.
- Underwriting agreementJul 2, 2026
The Company will pay the Designated Sales Agent a commission of 3.0% of the aggregate gross proceeds from each sale of the Common Stock and has agreed to provide the Sales Agents with customary indemnification and contribution rights, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended.
- Partnership or collaborationJun 4, 2026
On June 2, 2026, Veru Inc. (the "Company") entered into a clinical supply agreement (the "Supply Agreement") with Novo Nordisk A/S ("Novo Nordisk") in conjunction with the Company's Phase 2b PLATEAU clinical study. Under the terms of the Supply Agreement, the Company is solely responsible for conducting and sponsoring the Phase 2b PLATEAU clinical study while Novo Nordisk will supply Wegovy® to the Company at no charge and as required for the conduct of the Phase 2b PLATEAU study.
- Underwriting agreementOct 30, 2025
On October 30, 2025, Veru Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Canaccord Genuity LLC, as representative of the underwriters named therein (the "Underwriters"), relating to the offering, issuance and sale (the "Offering") of 8,400,000 shares of the Company's common stock...at a combined public offering price of $3.00 per Share and accompanying Series A Warrant and Series B Warrant.
- Settlement agreementSep 26, 2025
On September 22, 2025, the Company and the Borrower entered into a Settlement Agreement and Release (the 'Settlement Agreement'), whereby the Company agreed to accept a cash payment of $6,326,155.41, 3,125 shares of the Borrower's Series D Convertible Preferred Stock and 846,975 warrants to purchase shares of the Borrower's common stock in full satisfaction of all amounts due under the Promissory Notes.
Dividend history and stock splits
Veru Inc.'s recent dividend payments and stock splits.
Dividends
- $0.07ex-div Apr 28, 2014
- $0.07ex-div Jan 27, 2014
- $0.07ex-div Oct 28, 2013
- $0.07ex-div Jul 29, 2013
Splits
- 1-for-10Aug 11, 2025
VERU short interest
How heavily VERU is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.9
- Short interest
- 1.47M
- Avg volume
- 298.24K
As of · reported to FINRA twice monthly.
VERU news
The latest news and headlines about Veru Inc. (VERU).
- Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma PipelinepositiveBenzinga· Dec 31, 2024
- Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) BusinesspositiveGlobeNewswire Inc.· Dec 31, 2024
- Sexual Wellness Market to Witness 4.7% CAGR by 2031 | SkyQuest TechnologypositiveBenzinga· Oct 3, 2024
- Veru to Participate in the Leerink Therapeutics Forum: I&I and MetabolismGlobeNewswire Inc.· Jul 2, 2024
- Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific SessionsGlobeNewswire Inc.· Jun 24, 2024
Frequently asked questions
What is the Veru Inc. (VERU) stock price today?
Veru Inc. (VERU) is trading at $2.18 (+2.83% on the day) as of 2:18:18 PM EST on Nov 9, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Veru Inc.?
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin.
What is the short interest in VERU?
As of Oct 15, 2026, VERU has 1.47M shares short and 4.9 days to cover.
Does Veru Inc. (VERU) pay a dividend?
Yes. Veru Inc. (VERU)'s most recent dividend was $0.07 per share, with an ex-dividend date of Apr 28, 2014. Full VERU dividend history is available from the Massive API.
What exchange is VERU listed on?
Veru Inc. (VERU) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of VERU with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a VERU analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.